Related Experiment Videos
[Blood replacement in heart transplantation]
L von Segesser1, A Laske, E R Schmid
1Klinik für Herzgefässchirurgie, Universitätsspital, Zürich, Schweiz.
Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1989
Summary
Orthotopic heart transplantation patients required significant blood product transfusions, averaging 24.2 units per patient. Transfusion of cytomegalic inclusion disease-free blood products is recommended to reduce post-transplant complications.
Area of Science:
- Cardiology
- Transfusion Medicine
Context:
- Analysis of blood product transfusion in 31 orthotopic heart transplant patients (1985-1987).
- Patients were NYHA functional class IV with mean left ventricular ejection fraction of 20%.
Purpose:
- To analyze transfusion requirements and outcomes in orthotopic heart transplantation.
- To assess the impact of blood product transfusion on patient survival and complications.
Summary:
- Mean transfusion requirement was 24.2 units of blood products per patient.
- Red cells, concentrated red cells, fresh frozen plasma, and platelets were the most frequently transfused components.
- In-hospital mortality was 3%, with 87% actuarial survival at 33 months.
Impact:
- 26% of survivors experienced cytomegalic inclusion disease (CID) post-transplantation.
- Recommends transfusion of CID-free blood products to mitigate post-transplant complications.